Boehringer Ingelheim to Develop Dicerna's GalXC RNAi Candidate for NASH
Shots:
- Boehringer Ingelheim has accepted a GalXC RNAi candidate (DCR-LIV2) for advancement under the existing agreement b/w the companies for the discovery and development of novel therapies for chronic liver diseases
- Dicerna will receive $170M as development and commercial milestones related to DCR-LIV2 and is eligible to receive royalties on net sales of the therapy
- Boehringer Ingelheim will evaluate DCR-LIV2 for the treatment of NASH
Ref: Dicerna | Image: New England Real Estate Journal
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com